obsolete_cystic fibrosis: ['A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather. -- 2003', 'A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
60 |
4. Check minimum number of eventsNone |
60 |
5. Include endpointsNone |
60 |
6. Filter based on genotype QC (FinnGen only) |
57 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cystic fibrosis, other manifestations/unspecified
based on the number of shared cases.
Similar with more cases:
- Cystic fibrosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 334 | 163 | 167 |
| Only index persons | 240 | 118 | 122 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | 0.00 |
| Only index persons | 0.00 | 0.00 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 17.26 | 21.54 | 12.15 |
| Only index persons | 16.03 | 20.33 | 11.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 57 | 32 | 25 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 10.29 | 14.91 | 4.37 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 59
- Matched controls
- 590
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E84.9
ICD-10 Finland
Cystic fibrosis, unspecified
+∞
56.7
45
*
E84.0
ICD-10 Finland
Cystic fibrosis with pulmonary manifestations
+∞
43.1
36
*
304
Kela drug reimbursment
Dornase alfa
+∞
37.5
32
*
R05CB13
ATC
dornase alfa (desoxyribonuclease); inhalant
+∞
37.5
32
*
J01GB01
ATC
tobramycin; inhalant, parenteral
+∞
33.6
29
*
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
168.9
32.9
32
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
210.5
32.5
31
*
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
516.5
30.8
28
*
E84.1
ICD-10 Finland
Cystic fibrosis with intestinal manifestations
+∞
28.4
25
*
E84.8
ICD-10 Finland
Cystic fibrosis with other manifestations
+∞
25.9
23
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
37.1
24.6
32
18
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
14.8
23.5
28
34
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
341.7
23.4
22
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
42.8
22.8
28
12
TGC00
NOMESCO Finland
Bronchial lavation
158.9
21.1
21
*
GD1AD
NOMESCO Finland
Thorax CT examination
46.6
20.9
25
9
J18.9
ICD-10 Finland
Pneumonia, unspecified
11.5
20.6
38
80
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
11.4
20.5
33
59
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
29.9
19.9
27
16
J01XB01
ATC
colistin; inhalant, parenteral
+∞
19.9
18
*
2770A
ICD-9 Finland
Other and unspecified disorders of metabolism, Cystic fibrosis
+∞
18.7
17
*
J01MA12
ATC
levofloxacin; systemic
9.9
17.6
30
56
UGC12
NOMESCO Finland
Flexible bronchoscopy
27.8
17.5
24
14
L04AA06
ATC
mycophenolic acid; systemic
84.3
16.9
18
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
30.8
16.7
22
11
E84
ICD-10 Finland
Cystic fibrosis
+∞
16.4
15
*
J32.4
ICD-10 Finland
Chronic pansinusitis
214.6
16.4
16
*
R4190
NOMESCO Finland
Nutritional therapy
24.2
16.1
23
15
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
36.7
16.0
20
8
XG410
NOMESCO Finland
Flow-volume spirometry
36.7
16.0
20
8
TDM10
NOMESCO Finland
Puncture of maxillary antrum
32.6
15.5
20
9
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
+∞
15.2
14
*
L04AD02
ATC
tacrolimus; systemic
196.8
15.2
15
*
Z94.2
ICD-10 Finland
Lung transplant status
196.8
15.2
15
*
R4110
NOMESCO Finland
Physiotherapy
8.2
15.1
35
89
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
18.4
15.1
24
21
J01MA02
ATC
ciprofloxacin; systemic
8.4
15.1
39
111
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
8.1
14.8
31
71
UDH02
NOMESCO Finland
Rhinopharyngoscopy
16.7
14.5
24
23
GD1AA
NOMESCO Finland
Thorax X-ray examination
9.6
14.5
46
159
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
30.2
14.5
19
9
127
Kela drug reimbursment
Transplant complication
46.6
14.4
17
5
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
20.9
14.1
21
15
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
14.1
13
*
J33.0
ICD-10 Finland
Polyp of nasal cavity
53.6
14.0
16
*
R03BA02
ATC
budesonide; inhalant
7.8
13.9
28
61
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.6
13.8
37
107
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
163.3
13.0
13
*
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
13.0
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.9
12.7
23
44
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
59.9
12.5
14
*
ZX120
NOMESCO Finland
Intravenous
18.0
12.2
19
15
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
19.3
11.9
18
13
R03AK06
ATC
salmeterol and fluticasone; inhalant
8.1
11.9
20
35
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
17.9
11.6
18
14
602
Kela drug reimbursment
Children's severe malnutrition
35.8
11.3
14
5
TPX10
NOMESCO Finland
Implantation of vascular injection port
40.8
10.8
13
*
3045, ,
Kela drug reimbursment
+∞
10.7
10
*
R07AX02
ATC
ivacaftor; oral
+∞
10.7
10
*
R07AX32
ATC
ivacaftor, tezacaftor and elexacaftor; oral
+∞
10.7
10
*
B05XA03
ATC
sodium chloride; parenteral
+∞
10.7
10
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.1
10.7
28
76
WX404
NOMESCO Finland
Intravenous generell anesthesy
6.1
10.5
27
72
R03BA05
ATC
fluticasone; inhalant
6.2
10.5
26
67
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
13.8
10.4
18
18
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
17.7
10.4
16
12
Z3226
NOMESCO Finland
Physiotherapist
6.2
10.3
25
63
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
32.6
10.3
13
5
J01MA14
ATC
moxifloxacin; systemic
14.4
10.1
17
16
R04.2
ICD-10 Finland
Haemoptysis
66.3
10.0
11
*
TPH04
NOMESCO Finland
Cathetrisation of vein
6.1
10.0
24
60
ZXA10
NOMESCO Finland
Bilateral
5.9
9.8
24
61
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
5.8
9.8
25
66
DPA25
NOMESCO Finland
Trephine of frontal sinus through nose
118.2
9.7
10
*
A10AB05
ATC
insulin aspart; parenteral
11.8
9.7
18
21
XX4BW, ,
NOMESCO Finland
+∞
9.6
9
*
27300
ICD-8 Finland
Other and unspecified congenital disorders of metabolism, Cystic fibrosis (mucoviscidosis)
+∞
9.6
9
*
215
Kela drug reimbursment
Diabetes, non-insulin-treated
5.9
9.4
23
58
UDM02
NOMESCO Finland
Sinoscopy
44.2
9.4
11
*
UJF32
NOMESCO Finland
Coloscopy
6.1
9.3
21
49
103
Kela drug reimbursment
Diabetes, insulin-treated
5.5
9.0
24
65
WX302
NOMESCO Finland
Thoracal epidural anesthesy
24.6
8.9
12
6
R01AD08
ATC
fluticasone; nasal
5.2
8.8
28
88
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
18.0
8.7
13
9
K90.3
ICD-10 Finland
Pancreatic steatorrhoea
104.4
8.7
9
*
DHB20
NOMESCO Finland
Polypectomy of internal nose
+∞
8.5
8
*
DPA30
NOMESCO Finland
Sphenotomy
+∞
8.5
8
*
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
26.5
8.4
11
5
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
16.2
8.4
13
10
OAB50, ,
SPAT
10.5
8.3
16
20
J01CF05
ATC
flucloxacillin; systemic
9.1
8.0
17
25
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
52.2
8.0
9
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
52.2
8.0
9
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
29.5
7.9
10
*
Z3229
NOMESCO Finland
Other healthcare associate professional
9.1
7.6
16
23
R05CB02
ATC
bromhexine; systemic
91.1
7.6
8
*
RS123, ,
NOMESCO Finland
91.1
7.6
8
*
A05AA02
ATC
ursodeoxycholic acid; oral
18.9
7.6
11
7
Z2446
NOMESCO Finland
Social worker
9.6
7.5
15
20
J33.8
ICD-10 Finland
Other polyp of sinus
+∞
7.4
7
*
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
4.4
7.3
33
133
Z31.5
ICD-10 Finland
Genetic counselling
9.2
7.3
15
21
ZXE10
NOMESCO Finland
More than one and less than three hours
4.3
7.2
31
120
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
19.6
7.0
10
6
A02BA03
ATC
famotidine; systemic
26.0
6.9
9
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
7.4
6.8
16
28
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
77.9
6.6
7
*
J47
ICD-10 Finland
Bronchiectasis
77.9
6.6
7
*
UDC00
NOMESCO Finland
Ear microscopy
9.5
6.5
13
17
WX872
NOMESCO Finland
Intensive care
10.4
6.4
12
14
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
10.4
6.4
12
14
ZXE40
NOMESCO Finland
More than seven and less than nine hours
30.3
6.4
8
*
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
30.3
6.4
8
*
R73.9
ICD-10 Finland
Hyperglycaemia, unspecified
30.3
6.4
8
*
Z94.0
ICD-10 Finland
Kidney transplant status
30.3
6.4
8
*
V07AB
ATC
Solvents and diluting agents, incl. irrigating solutions
+∞
6.4
6
*
DM1BG
NOMESCO Finland
Paranasal sinuses and face area standard MRI examination with high intensity magnet
+∞
6.4
6
*
J02AC04
ATC
posaconazole; systemic
+∞
6.4
6
*
H02AB06
ATC
prednisolone; systemic
3.9
6.2
34
153
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
8.4
6.1
13
19
E14.9
ICD-10 Finland
Unspecified diabetes mellitus, without complications
17.3
6.1
9
6
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
17.3
6.1
9
6
WZC30
NOMESCO Finland
Teaching
4.9
6.0
16
42
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
31
21.37
31.86
4.0
1.2
—
—
—
0
0
31
13
48.32
25.75
6.3
2.5
3.33
3.15
g/l
0.19
31
13
29
12
45.76
23.92
7.2
3.4
158.41
160.92
%
0.04
29
12
27
8
60.20
23.78
7.0
2.1
—
—
—
0
0
30
45
12.53
21.47
8.9
2.3
0.21
0.23
g/l
0.87
30
40
27
13
36.85
21.18
5.2
1.6
—
—
—
0
0
33
57
11.87
21.13
4.5
1.7
—
—
—
0
0
27
14
34.17
20.74
4.6
1.6
—
—
—
0
0
37
75
11.55
20.72
5.7
2.1
—
—
—
0
0
31
54
10.99
19.51
5.1
1.8
—
—
—
0
0
22
6
56.79
19.29
4.0
1.2
—
—
—
0
0
36
76
10.59
19.24
4.7
2.4
11.49
12.70
umol/l
0.56
36
71
23
9
40.58
18.71
5.6
1.1
—
—
—
0
0
23
11
33.13
17.76
4.7
1.2
—
—
—
0
0
22
9
37.78
17.63
4.1
1.2
—
—
—
0
0
22
9
37.78
17.63
4.4
1.8
—
—
—
0
0
24
14
27.82
17.53
4.9
1.1
—
—
—
0
0
22
13
26.04
15.87
30.7
4.9
115.17
—
iu/ml
—
6
0
51
202
12.20
14.40
27.3
6.8
1.20
1.21
mmol/l
0.45
44
165
30
68
7.94
14.39
5.1
2.5
2.46
2.42
g/l
0.11
30
63
48
186
9.48
13.06
19.4
6.9
1.21
1.21
mmol/l
0.08
48
166
37
116
6.87
12.44
5.7
1.9
1.38
1.13
mg/l
0.13
26
80
26
59
7.09
12.20
11.7
11.9
103.12
105.15
mmol/l
0.82
26
59
41
161
6.07
10.18
11.3
2.4
26.32
29.50
u/l
0.58
41
149
13
7
23.25
9.43
3.0
1.9
—
—
—
0
0
13
8
20.33
9.04
3.2
1.1
—
—
—
0
0
13
10
16.22
8.35
3.3
1.1
—
—
—
0
0
30
105
4.78
8.17
7.0
4.1
13.32
12.55
mg/mmol
0.02
25
62
11
7
18.89
7.56
1.3
1.6
95.91
123.00
%
—
11
7
12
11
13.32
7.18
4.1
1.8
—
—
—
0
0
10
6
19.64
7.02
2.0
1.0
—
—
—
0
0
10
6
19.64
7.02
1.1
1.5
75.70
113.33
%
—
10
6
6
0
+∞
6.35
1.2
0.0
—
—
—
0
0
10
9
13.06
6.05
1.1
1.3
—
—
—
0
0
15
28
6.81
6.05
3.9
1.6
—
—
—
0
0
16
33
6.25
6.00
6.8
3.7
1.23
1.24
mmol/l
0.11
16
27
23
82
3.96
5.81
6.7
2.9
1.73
1.35
e6/l
0.14
15
40
5
0
+∞
5.28
7.2
0.0
—
—
—
0
0
33
158
3.47
5.24
1.8
1.5
0.52
1.18
u/ml
—
6
28
34
169
3.39
5.03
10.1
3.5
—
—
—
0
0
11
20
6.50
4.55
1.5
1.2
118.00
164.22
au/ml
—
5
9
13
30
5.25
4.46
3.2
2.8
67.63
78.73
ml/min/173m2
—
8
11
11
21
6.18
4.40
1.5
1.1
—
—
—
0
0
11
22
5.89
4.25
1.4
1.1
—
—
—
0
0
8
10
9.03
4.21
1.3
1.3
—
—
—
0
0
8
10
9.03
4.21
4.9
2.0
13.82
5.14
pmol/l
—
8
10
12
28
5.10
4.10
2.3
2.1
—
—
—
0
0
8
11
8.20
4.00
5.3
1.5
—
—
—
0
0
6
5
13.13
3.85
2.2
1.4
—
—
—
0
0
6
5
13.13
3.85
1.2
1.2
102.83
117.00
pmol/l
—
6
5
6
6
10.93
3.58
2.7
1.2
—
—
—
0
0
7
12
6.45
3.12
3.4
2.1
0.40
0.68
ug/l
—
7
12
5
5
10.75
3.03
3.4
1.2
—
—
—
0
0
53
417
3.66
2.94
6.5
3.6
1.29
1.21
mmol/l
0.38
47
382
6
10
6.53
2.77
2.3
1.3
—
—
—
0
0
10
30
3.80
2.76
13.0
15.2
26.34
24.43
mmol/l
—
10
30
50
385
2.95
2.68
7.0
4.2
14.40
14.63
pmol/l
0.23
45
348
8
20
4.45
2.67
2.8
1.3
—
—
—
0
0
5
7
7.66
2.60
1.2
1.0
—
—
—
0
0
54
443
3.58
2.48
8.0
4.1
1.47
1.45
mmol/l
0.12
49
410
5
8
6.70
2.42
2.0
1.8
15.36
15.15
%
—
5
8
54
448
3.42
2.29
8.3
4.2
4.03
4.62
mmol/l
3.20
49
415
12
49
2.82
2.27
3.3
4.3
18.33
30.91
u/l
—
6
44
29
181
2.18
2.22
2.3
1.7
81.32
99.00
pmol/l
1.38
15
81
20
108
2.29
2.16
4.5
3.0
—
—
—
0
0
5
10
5.34
2.11
1.6
1.1
—
—
—
0
0
5
10
5.34
2.11
1.6
1.1
—
—
—
0
0
6
15
4.32
2.09
1.7
1.1
—
—
—
0
0
8
172
0.38
2.03
1.5
1.8
—
—
—
0
0
5
11
4.85
1.98
1.8
1.4
—
—
—
0
0
37
262
2.11
1.97
5.8
3.5
0.00
0.00
estimate
-0.00
16
59
17
89
2.28
1.95
6.0
2.8
0.21
0.62
e6/l
1.19
11
46
25
154
2.08
1.92
3.8
3.3
34.04
48.26
ng/l
0.28
18
91
5
12
4.44
1.86
2.2
1.1
—
—
—
0
0
37
266
2.05
1.85
5.8
3.5
0.00
0.00
estimate
-0.00
15
60
24
148
2.05
1.82
4.4
3.8
0.00
0.00
estimate
-0.00
14
57
37
269
2.01
1.76
5.8
3.5
0.00
0.00
estimate
-0.00
13
60
12
57
2.39
1.69
3.8
4.2
263.83
226.50
u/l
0.29
12
52
13
65
2.28
1.64
1.7
1.6
1052.63
1284.50
nmol/l
—
8
44
6
21
3.06
1.55
2.3
2.0
0.92
1.19
g/l
—
6
21
6
21
3.06
1.55
2.3
2.0
0.22
0.21
g/l
—
6
21
10
46
2.41
1.49
3.9
3.7
—
—
—
0
0
15
87
1.97
1.30
1.2
1.4
28.60
14.56
iu/ml
—
5
19
0
33
0.00
1.20
0.0
1.6
—
55.72
—
0
26
31
233
1.70
1.15
5.1
3.0
—
—
estimate
—
0
0
22
152
1.71
1.10
5.0
2.8
0.00
0.00
estimate
-0.00
14
48
0
29
0.00
1.01
0.0
1.8
—
—
—
0
0
0
30
0.00
1.00
0.0
1.5
—
0.97
—
0
15
0
30
0.00
1.00
0.0
1.5
—
1.07
—
0
15
0
30
0.00
1.00
0.0
1.5
—
0.86
—
0
15
5
28
1.86
0.68
21.2
16.7
0.84
0.69
%
—
5
28
5
30
1.73
0.63
2.2
1.3
—
—
—
0
0
0
22
0.00
0.60
0.0
1.2
—
42.73
—
0
22
25
201
1.42
0.59
4.7
3.3
0.00
0.00
estimate
-0.00
15
47
5
81
0.58
0.50
2.2
2.3
—
—
—
0
0
5
32
1.61
0.43
21.2
15.1
1.30
1.63
%
—
5
32
0
16
0.00
0.42
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
7
52
1.39
0.33
1.0
1.0
—
—
—
0
0
11
139
0.74
0.31
1.5
3.0
—
—
—
0
0
5
42
1.21
0.22
1.2
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
15.88
—
0
10
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
8
91
0.86
0.07
2.1
2.5
—
—
—
0
0
42
411
1.08
0.03
4.7
3.6
—
—
—
0
0
12
127
0.93
0.02
1.4
2.9
—
—
—
0
0
10
98
1.02
0.00
1.6
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
14.17
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
315.71
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
-0.00
19.8
4.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_CYSTFIBRO_NAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_CYSTFIBRO_NAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_CYSTFIBRO_NAS – Cystic fibrosis, other manifestations/unspecified
GWS hits: 9
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data